(Total Views: 529)
Posted On: 07/08/2021 11:15:40 AM
Post# of 72440
Another Great Post by Billy10US
Kick start to world wide recognition is 5 days away. Presentation topic: Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
Normally several hundreds of the most renown virologists attend this event. But due to Covid it will be a virtual meeting. That I see as good news. Why? Because it can now be attended by thousands of the most highly regarded virologists, general physicians, medical institutions, researchers and BP that wouldn't have attended the meeting.
Let's be realistic other than this board very few people know the genesis of Brilacidin and its subsequent successes at the RBL labs. The presentation at the virology meeting July 19-23 will be given by : George Mason’s Regional Biocontainment Laboratory that is recognized globally as a premier institution for medical research and not by Leo who very few people know of at this time.
Among topics that will probably be discussed are:
. Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing COVID-19.
. In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index of 426.
. The primary mechanism of action of Brilacidin appears to disrupt viral integrity and block viral entry.
. Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2.
Additionally, I'm certain that the presentation will also include that clinical trial results will be forthcoming in the next few weeks with top line results and un-blinded data that will and cannot be refuted any longer. I speculate that this presentation will be initially discussed by thousands of eyes and ears to start with and news will be exponentially spread. Once DD by those in the know is completed. I suspect many will contact Dr. William F. DeGrado directly who I quote:
“Brilacidin’s demonstration of potent antiviral activity against SARS-CoV-2 is important, particularly given its apparent ability to impact the virus directly,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco and Scientific Advisor to Innovation Pharmaceuticals. “This antiviral mechanism of action suggests Brilacidin might be able to inhibit other viruses and be less prone to resistance developing due to viral mutations—a weak spot for other antivirals, antibody-based treatments and vaccines. I am extremely hopeful Brilacidin will emerge as an effective COVID-19 treatment given the ongoing worldwide need for COVID-19 therapeutics.”
Then awareness that Ipix will soon present: New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium.
IMO the knocking on IPIX's door will be deafening very soon. All the best to everyone.
I welcome thoughtful opinions pro and con discussed in civility
Kick start to world wide recognition is 5 days away. Presentation topic: Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
Normally several hundreds of the most renown virologists attend this event. But due to Covid it will be a virtual meeting. That I see as good news. Why? Because it can now be attended by thousands of the most highly regarded virologists, general physicians, medical institutions, researchers and BP that wouldn't have attended the meeting.
Let's be realistic other than this board very few people know the genesis of Brilacidin and its subsequent successes at the RBL labs. The presentation at the virology meeting July 19-23 will be given by : George Mason’s Regional Biocontainment Laboratory that is recognized globally as a premier institution for medical research and not by Leo who very few people know of at this time.
Among topics that will probably be discussed are:
. Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing COVID-19.
. In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index of 426.
. The primary mechanism of action of Brilacidin appears to disrupt viral integrity and block viral entry.
. Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2.
Additionally, I'm certain that the presentation will also include that clinical trial results will be forthcoming in the next few weeks with top line results and un-blinded data that will and cannot be refuted any longer. I speculate that this presentation will be initially discussed by thousands of eyes and ears to start with and news will be exponentially spread. Once DD by those in the know is completed. I suspect many will contact Dr. William F. DeGrado directly who I quote:
“Brilacidin’s demonstration of potent antiviral activity against SARS-CoV-2 is important, particularly given its apparent ability to impact the virus directly,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco and Scientific Advisor to Innovation Pharmaceuticals. “This antiviral mechanism of action suggests Brilacidin might be able to inhibit other viruses and be less prone to resistance developing due to viral mutations—a weak spot for other antivirals, antibody-based treatments and vaccines. I am extremely hopeful Brilacidin will emerge as an effective COVID-19 treatment given the ongoing worldwide need for COVID-19 therapeutics.”
Then awareness that Ipix will soon present: New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium.
IMO the knocking on IPIX's door will be deafening very soon. All the best to everyone.
I welcome thoughtful opinions pro and con discussed in civility
(9)
(0)Scroll down for more posts ▼
